Risk and survival of third primary cancers in a population-based cohort of prostate cancer survivors.
2/5 보강
TL;DR
Among males with a prostate FPC that are diagnosed with an SPC, just over 10% are expected to be diagnosed with a TPC within 20 years, and these have a nearly two-fold higher death hazard than those with an SPC only.
OpenAlex 토픽 ·
Multiple and Secondary Primary Cancers
Cancer Diagnosis and Treatment
Genetic factors in colorectal cancer
Among males with a prostate FPC that are diagnosed with an SPC, just over 10% are expected to be diagnosed with a TPC within 20 years, and these have a nearly two-fold higher death hazard than those w
APA
Paulo M. Sá, José Taveira-Barbosa, et al. (2026). Risk and survival of third primary cancers in a population-based cohort of prostate cancer survivors.. European journal of cancer prevention : the official journal of the European Cancer Prevention Organisation (ECP), 35(3), 281-288. https://doi.org/10.1097/CEJ.0000000000000977
MLA
Paulo M. Sá, et al.. "Risk and survival of third primary cancers in a population-based cohort of prostate cancer survivors.." European journal of cancer prevention : the official journal of the European Cancer Prevention Organisation (ECP), vol. 35, no. 3, 2026, pp. 281-288.
PMID
40402538 ↗
Abstract 한글 요약
[OBJECTIVE] To estimate the long-term risk and survival of third primary cancers (TPCs) among prostate first primary cancer (FPC) survivors.
[METHODS] A population-based cohort of 13 222 males with a prostate FPC diagnosed between 2000 and 2009, registered by the North Region Cancer Registry of Portugal, was followed until 2021 for TPCs and vital status. We estimated the cumulative incidence of TPCs and the risk of death among TPCs. TPCs were compared to matched patients with a second primary cancer (SPC) only (1:1, by age group, the time between FPC and SPC, and SPC site) for risk and adjusted hazard of death.
[RESULTS] For a period of up to 22 years after a prostate cancer diagnosis, 169 TPCs were identified, predominantly, in digestive, intrathoracic, and urinary tract organs; this corresponds to 15- and 20-year cumulative incidences [95% confidence interval (CI)] of 1.2% (1.0-1.4%) and 1.5% (1.2-1.8%), respectively, among the FPCs, and 9.1% (7.6-10.5%) and 12.0% (8.2-15.9%), respectively, among the SPCs. The 15-year all-cause cumulative mortality was 88.2% (82.2-94.3%) among TPCs and 75.7% (69.6-81.7%) among SPC only patients; the corresponding age-adjusted hazard ratio (95% CI) was 1.79 (1.37-2.34).
[CONCLUSIONS] Among males with a prostate FPC that are diagnosed with an SPC, just over 10% are expected to be diagnosed with a TPC within 20 years, and these have a nearly two-fold higher death hazard than those with an SPC only.
[METHODS] A population-based cohort of 13 222 males with a prostate FPC diagnosed between 2000 and 2009, registered by the North Region Cancer Registry of Portugal, was followed until 2021 for TPCs and vital status. We estimated the cumulative incidence of TPCs and the risk of death among TPCs. TPCs were compared to matched patients with a second primary cancer (SPC) only (1:1, by age group, the time between FPC and SPC, and SPC site) for risk and adjusted hazard of death.
[RESULTS] For a period of up to 22 years after a prostate cancer diagnosis, 169 TPCs were identified, predominantly, in digestive, intrathoracic, and urinary tract organs; this corresponds to 15- and 20-year cumulative incidences [95% confidence interval (CI)] of 1.2% (1.0-1.4%) and 1.5% (1.2-1.8%), respectively, among the FPCs, and 9.1% (7.6-10.5%) and 12.0% (8.2-15.9%), respectively, among the SPCs. The 15-year all-cause cumulative mortality was 88.2% (82.2-94.3%) among TPCs and 75.7% (69.6-81.7%) among SPC only patients; the corresponding age-adjusted hazard ratio (95% CI) was 1.79 (1.37-2.34).
[CONCLUSIONS] Among males with a prostate FPC that are diagnosed with an SPC, just over 10% are expected to be diagnosed with a TPC within 20 years, and these have a nearly two-fold higher death hazard than those with an SPC only.
🏷️ 키워드 / MeSH 📖 같은 키워드 OA만
🏷️ 같은 키워드 · 무료전문 — 이 논문 MeSH/keyword 기반
- A Phase I Study of Hydroxychloroquine and Suba-Itraconazole in Men with Biochemical Relapse of Prostate Cancer (HITMAN-PC): Dose Escalation Results.
- Self-management of male urinary symptoms: qualitative findings from a primary care trial.
- Clinical and Liquid Biomarkers of 20-Year Prostate Cancer Risk in Men Aged 45 to 70 Years.
- Diagnostic accuracy of Ga-PSMA PET/CT versus multiparametric MRI for preoperative pelvic invasion in the patients with prostate cancer.
- Comprehensive analysis of androgen receptor splice variant target gene expression in prostate cancer.
- Clinical Presentation and Outcomes of Patients Undergoing Surgery for Thyroid Cancer.